Building on a Foundation of Strength
The needs of people with immune-mediated disease drive our work to create innovative, effective solutions.
Our Vision for the Future
For more than 20 years, we have focused on forging new paths for the treatment of immune-mediated diseases. Years of clinical studies have revealed that, despite significant advances, patients’ needs persist. As we look forward, our commitment to making a remarkable impact in patients’ lives remains and we must grow to find solutions where they’re most needed. We have a bold vision for the future: one in which we have an answer for even more patients. Guided by real patient experiences, we’re investigating three key focus areas within immunology.
Leading the Way
We are relentlessly developing a robust pipeline of potential new therapies to address different targets, and we are using a variety of technology platforms—from biologics to small molecules to bispecifics—to find and deliver solutions for patients’ biggest challenges.
We are even evaluating a new platform called DVD-Ig, a technology with the potential to combine two different antibodies targeting two different disease pathways into one medicine.
Current and Prospective Targets
Several targets play an important role in the advancement of our robust immunology pipeline.
A cytokine that contributes to the induction and maintenance of the inflammatory immune response
Two related cytokine proteins, IL-1 α/β, play a role in acute and chronic inflammation
A cytokine that plays a key role in immune-mediated inflammatory disease
A cytokine that induces tissue inflammation, epithelial hypertrophy and may play a role in asthma
A cytokine produced by T cells that mediate inflammatory responses when produced in excess
A cytokine that shares a subunit with IL-12 and works to mediate inflammatory responses
A protein that binds to DNA and regulates the production of other key pro-inflammatory proteins
An enzyme that signals and initiates the response of other cytokines involved in the body’s immune response
A protein receptor expressed by B cells, macrophages and dendritic cells that is involved in mediating inflammatory responses
An enzyme that activates the production and growth of B cells, which produce antibodies that help the body protect itself
Want to learn more about our targeted technology platforms and therapeutic targets?
Explore Our Portfolio
Risankizumab is an investigational treatment that selectively blocks interleukin-23 (IL-23), a key signaling agent that has been linked to a number of chronic immune-mediated diseases. Risankizumab is being evaluated in multiple inflammatory diseases, including psoriasis, Crohn’s disease and psoriatic arthritis. Efficacy and safety have not been established.
Upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an important role in the pathophysiology of rheumatoid arthritis and other immune-mediated inflammatory disorders. Upadacitinib is being studied in rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis. Efficacy and safety have not been established.
HUMIRA is an anti-TNF monoclonal antibody.
We’re focused on changing the lives of patients with rheumatoid arthritis, psoriatic arthritis, uveitis, juvenile idiopathic arthritis, and ankylosing spondylitis.
Patients with plaque psoriasis, psoriatic arthritis, atopic dermatitis and hidradenitis suppurativa drive our dermatology work.
Behind the Science
Immunology at AbbVie: In the Lab with Lisa Olson
AbbVie’s Lisa Olson, PhD, vice president of immunology research, shares how AbbVie is approaching innovation to lead the way in the treatment of immune-mediated diseases with next generation breakthrough therapies.
Join Our Team
Our team of immunology experts is focused on improving the standard of care for this generation and the next. We’re committed, curious, and passionate; and we’re hiring.
Search all immunology jobs
AbbVie Immunology In the News
AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting
AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis